Constrictor responses of resistance arterioles during diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 44, Issue 3, 1999, Pages 147-156

  Mayhan, William G ^a   Irvine, Scott D ^a   Sharpe, Glenda M ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Arterioles; Endothelin 1; N(G) monomethyl L arginine (L NMMA); Nitric oxide; Norepinephrine; Thromboxane

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ENDOTHELIN 1; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NORADRENALIN;

ANIMAL MODEL; ARTERIOLE; ARTERY DIAMETER; ARTICLE; CHEEK POUCH; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; HAMSTER; MALE; MICROCIRCULATION; NONHUMAN; REGIONAL PERFUSION; STREPTOZOCIN DIABETES; VASCULAR RESISTANCE;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANIMALS; ARTERIOLES; CHEEK; CRICETINAE; DIABETES MELLITUS, EXPERIMENTAL; ENDOTHELIN-1; ENZYME INHIBITORS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MESOCRICETUS; NITRIC OXIDE; NOREPINEPHRINE; OMEGA-N-METHYLARGININE; RANDOM ALLOCATION; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 0033036088     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(99)00031-5     Document Type: Article

References (58)

1. Tomlinson K.C., Gardiner S.M., Hebden R.A., Bennett T. Functional consequences of streptozotocin-induced diabetes mellitus, with particular reference to the cardiovascular system. Pharmacol. Rev. 44:1992;103-150.
2. Nathan D.M. Long-term complications of diabetes mellitus. New Engl. J. Med. 328:1993;1676-1685.
3. Pieper G.M., Gross G.J. Endothelial dysfunction in diabetes. Rubanyi G.M. Cardiovascular significance of endothelium-derived vasoactive factors, 1991;223-249 Futura Publishing Co, Mount Kisco, New York.
4. Mayhan W.G., Patel K.P., Sharpe G.M. Effect of L-arginine on reactivity of hamster cheek pouch arterioles during diabetes mellitus. Int. J. Microcirc. 17:1997;107-112.
5. Diederich D., Skopec J., Diederich A., Dai F.X. Endothelial dysfunction in mesenteric resistance arteries of diabetic rats: role of free radicals. Am. J. Physiol. 266:1994;H1153-H1161.
6. Shimizu K., Muramatsu M., Kakegawa Y. et al. Role of prostaglandin H2 as an endothelium-derived contracting factor in diabetic state. Diabetes. 42:1993;1246-1252.
7. Tesfamariam B., Jakubowski J.A., Cohen R.A. Contraction of diabetic rabbit aorta caused by endothelium-derived PGH2-TxA2. Am. J. Physiol. 257:1989;H1327-H1333.
8. King G.L., Ishii H., Koya D. Diabetic vascular dysfunctions: a model of excessive activation of protein kinase C. Kidney Int. 52:1997;S77-S85.
9. Pieper G.M., Langenstroer P., Gross G.J. Hydroxyl radicals mediate injury to endothelium-dependent relaxation in diabetic rat. Mol. Cell. Biochem. 122:1993;139-145.
10. Tesfamariam B., Cohen R.A. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am. J. Physiol. Heart Circ. Physiol. 263:1992;H321-H326.
11. Pieper G.M., Siebeniech W., Moore-Hilton G., Roza A.M. Reversal by L-arginine of the dysfunctional arginine/nitric oxide pathway in the endothelium of the genetic diabetic BB rat. Diabetologia. 40:1997;910-915.
12. Taylor P.D., Wickenden A.D., Mirrlees D.J., Poston L. Endothelial function in the isolated perfused mesentery and aortae of rats with streptozotocin induced diabetes: effect of treatment with the aldose reductase inhibitor, ponalrestat. Br. J. Pharmacol. 111:1994;42-48.
13. Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. Free Radical Biol. Med. 16:1994;383-391.
14. Bucala R., Tracey K.J., Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J. Clin. Invest. 87:1991;432-438.
15. Brownlee M., Cerami A., Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. New Engl. J. Med. 318:1988;1315-1321.
16. Vo P.A., Reid J.J., Rand M.J. Endothelial nitric oxide attenuates vasoconstrictor responses to nerve stimulation and noradrenaline in the rat tail artery. Eur. J. Pharmacol. 199:1991;123-125.
17. Dohi Y., Thiel M.A., Buhler F.R., Luscher T.F. Activation of endothelial L-arginine pathway in resistance arteries: effect of age and hypertension. Hypertension. 15:1990;170-179.
18. Kanmura Y., Itoh T., Kuriyama H. Mechanisms of vasoconstriction induced by 9,11-epithio-11,12-methano-thromboxane A2 in the rabbit coronary artery. Circ. Res. 60:1987;402-409.
19. Filep J.G., Foldes-Filep E., Rousseau A., Sirois P., Fournier A. Vascular responses to endothelin-1 following inhibition of nitric oxide synthesis in the conscious rat. Br. J. Pharmacol. 110:1993;1213-1221.
20. Lawrence E., Brain S.D. Responses to endothelins in the rat cutaneous microvasculature: a modulatory role of locally-produced nitric oxide. Br. J. Pharmacol. 106:1992;733-738.
21. Christlieb A.R., Janka H.U., Kraus B. et al. Vascular reactivity to angiotensin II and to norepinephrine in diabetic subjects. Diabetes. 25:1976;268-274.
22. Harris K.H., MacLeod K.M. Influence of the endothelium on contractile responses of arteries from diabetic rats. Eur. J. Pharmacol. 153:1988;55-64.
23. Taylor P.D., McCarthy A.L., Thomas C.R., Poston L. Endothelium-dependent relaxation and noradrenaline sensitivity in mesenteric resistance arteries of streptozotocin-induced diabetic rats. Br. J. Pharmacol. 107:1992;393-399.
24. McNally P.G., Watt P.A.C., Rimmer T., Burden A.C., Hearnshaw J.R., Thurston H. Impaired contraction and endothelium-dependent relaxation in isolated resistance vessels from patients with insulin-dependent diabetes mellitus. Clin. Sci. 87:1994;31-36.
25. Ramanadham S., Lyness W.H., Tenner T.E. Alterations in aortic and tail artery reactivity to agonists after streptozotocin treatment. Can. J. Physiol. Pharmacol. 62:1984;418-423.
26. G-nitro-L-arginine methyl ester in streptozotocin-induced diabetes mellitus. Br. J. Pharmacol. 106:1992;1035-1040.
27. Hodgson W.C., King R.G. Effects of glucose, insulin or aldose reductase inhibition on responses to endothelin-1 of aortic rings from streptozotocin-induced diabetic rats. Br. J. Pharmacol. 106:1992;644-649.
28. G-nitro-L-arginine methyl ester on regional haemodynamics in conscious rats with streptozotocin-induced diabetes mellitus. Br. J. Pharmacol. 103:1991;1321-1326.
29. Tammesild P.J., Hodgson W.C., King R.G. Increased sensitivity to endothelin-1 in isolated Krebs'-perfused kidneys of streptozotocin-diabetic rats. Clin. Exp. Pharmacol. Physiol. 19:1992;261-265.
30. Joyner W.L., Mayhan W.G., Johnson R.L., Phares C.K. Microvascular alterations develop in Syrian hamsters after the induction of diabetes mellitus by streptozotocin. Diabetes. 30:1981;93-100.
31. Phares C.K. Streptozotocin-induced diabetes in Syrian hamsters: new model of diabetes mellitus. Experientia. 36:1980;681-682.
32. Mayhan W.G., Joyner W.L. The effect of altering the external calcium concentration and a calcium channel blocker, verapamil, on microvascular leaky sites and dextran clearance in the hamster cheek pouch. Microvasc. Res. 28:1984;159-179.
33. Davis M.J., Joyner W.L., Gilmore J.P. Microvascular pressure distribution and responses of pulmonary allografts and cheek pouch arterioles in the hamster to oxygen. Circ. Res. 49:1981;125-132.
34. Joyner W.L., Davis M.J. Pressure profile along the microvascular network and its control. Federation Proc. 46:1987;266-269.
35. + channels. Eur. J. Pharmacol. 242:1993;109-112.
36. 2+ in the selective enhancement of contractile responses of arteries from diabetic rats to noradrenaline. Can. J. Physiol. Pharmacol. 72:1994;1544-1551.
37. Agrawal D.K., McNeill J.H. Vascular responses to agonists in rat mesenteric artery from diabetic rats. Can. J. Physiol. Pharmacol. 65:1987;1484-1490.
38. 2, but not noradrenaline, of aortae from rats with streptozotocin-induced diabetes mellitus. Br. J. Pharmacol. 104:1991;928-932.
39. Heath H., Brigden W.D., Canever J.V. Platelet adhesiveness and aggregation in relation to diabetic retinopathy. Diabetologia. 7:1971;308-315.
40. Mayne E.C., Bridges J.M., Weaver J.A. Platelet adhesiveness, platelet fibrinogen, and factor VIII levels in diabetes mellitus. Diabetologia. 36:1970;978-981.
41. Takahashi R., Shiraki M., Morita I., Ito H., Murota S., Orimo H. Platelet thromboxane synthesizing activity in non insulin dependent diabetes: correlation with diabetic retinopathy and diabetic treatment. Prost. Leukotr. Med. 17:1985;149-158.
42. Halushka P.V., Dollery C.T., MacDermot J. Thromboxane and prostacyclin in disease: a review. Q. J. Med. 208:1983;461-470.
43. Boura A.L.A., Hodgson W.C., King R.G. Sensivity changes of the perfused hindquarters vasculature in rats with alloxan induced diabetes mellitus. Clin. Exp. Pharmacol. Physiol. 14:1987;481-487.
44. Quilley J., McGiff J.C. Renal vascular responsiveness to arachidonic acid in experimental diabetes. Br. J. Pharmacol. 100:1990;336-340.
45. Mayhan W.G. Impairment of endothelium-dependent dilatation of cerebral arterioles during diabetes mellitus. Am. J. Physiol. 256:1989;H621-H625.
46. Mayhan W.G., Simmons L.K., Sharpe G.M. Mechanism of impaired responses of cerebral arterioles during diabetes mellitus. Am. J. Physiol. 260:1991;H319-H326.
47. Kawamura M., Naruse K., Ohgawara H. et al. Increased plasma endothelin in NIDDM patients with retinopathy. Diabetes Care. 15:1992;1396-1397.
48. Takahashi K., Ghatei M.A., Lam H.C., O'Halloran D.J., Bloom S.R. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia. 33:1990;306-310.
49. Yamauchi T., Ohnaka K., Takayanagi R., Umeda F., Nawata H. Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine aortic endothelial cells. Febs. Lett. 267:1990;16-18.
50. Takeda Y., Miyamori I., Yoneda T., Takeda R. Production of endothelin-1 from the mesenteric arteries of streptozotocin-induced diabetic rats. Life Sci. 48:1991;2553-2556.
51. Smulders R.A., Stehouwer C.D.A., Olthof C.G. et al. Plasma endothelin levels and vascular effects of intravenous L-arginine infusion in subjects with uncomplicated insulin-dependent diabetes mellitus. Clin. Sci. 87:1994;37-43.
52. Kanno K., Hirata Y., Shichiri M., Marumo F. Plasma endothelin-1 levels in patients with diabetes mellitus with or without vascular complication. J. Cardiovasc. Pharmacol. (Suppl. 7). 17:1991;S475-S476.
53. Nugent A.G., McGurk C., Hayes J.R., Johnston G.D. Impaired vasoconstriction to endothelin 1 in patients with NIDDM. Diabetes. 45:1996;105-107.
54. Tsunoda K., Abe K., Sato T., Yokosawa S., Yoshinaga K. Decreased conversion of big endothelin-1 to endothelin-1 in patients with diabetes mellitus. Clin. Exp. Pharmacol. Physiol. 18:1991;731-732.
55. Awazu M., Parker R.E., Harvie B.R., Ichikawa I., Kon V. Down-regulation of endothelin-1 receptors by protein kinase C in streptozotocin diabetic rats. J. Cardiovasc. Pharmacol. (Suppl. 7). 17:1991;S500-S502.
56. Ohishi K., Carmines P.K. Superoxide dismutase restores the influence of nitric oxide on renal arterioles in diabetes mellitus. J. Am. Soc. Nephrol. 5:1995;1559-1566.
57. Calver A., Collier J., Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J. Clin. Invest. 90:1992;2548-2554.
58. Schmetterer L., Findl O., Fasching P. et al. Nitric oxide and ocular blood flow in patients with IDDM. Diabetes. 46:1997;653-658.